Sugi Predict

Sugi Predict / Compounds / SCHEMBL2033392

SCHEMBL2033392

SCHEMBL2033392

COC[C@H]1O[C@@H](n2cnc3c(NC(=O)NC(=O)[C@@H](N)[C@@H](C)O)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TARS1 P26639 2/20 0.60
▸ ADORA3 P0DMS8 3/20 0.59
▸ P2RY12 Q9H244 2/20 0.55
▸ ADORA1 P30542 1/20 0.53
▸ IARS1 P41252 2/20 0.52
▸ P2RY2 P41231 1/20 0.52
▸ P2RY1 P47900 1/20 0.52
▸ P2RY6 Q15077 1/20 0.52
▸ BMPR1B O00238 1/20 0.51
▸ PRMT5 O14744 2/20 0.51
▸ WDR77 Q9BQA1 2/20 0.51
▸ LARS1 Q9P2J5 2/20 0.51
▸ DOT1L Q8TEK3 2/20 0.51
▸ PRMT1 Q99873 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17371761 0.91 TARS1 (0.58) TARS1P2RY12IARS1P2RY2P2RY1
SCHEMBL453954 0.91 ADORA2A (0.57) —
SCHEMBL453953 0.91 ADORA2A (0.57) —
SCHEMBL29421357 0.91 ADORA2A (0.57) —
SCHEMBL453952 0.91 ADORA2A (0.57) —
SCHEMBL16555098 0.88 TARS1 (0.54) TARS1BMPR1BPRMT5WDR77DOT1L
SCHEMBL2056705 0.88 ADORA3 (0.60) TARS1ADORA3P2RY12ADORA1PRMT5
SCHEMBL6429185 0.86 ADORA3 (0.66) TARS1ADORA3P2RY12ADORA1PRMT5
SCHEMBL28630248 0.85 ADORA2A (0.57) —
SCHEMBL5155877 0.85 TARS1 (0.62) TARS1P2RY12ADORA1IARS1PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3417062-B1 EXCISION OF RETROVIRAL NUCLEIC ACID SEQUENCES UNIV TEMPLE (US) 2024-06-26 — — EP disclosed
EP-4385567-A2 METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION Temple University Of The Commonwealth System Of Higher Education (US) 2024-06-19 — — EP disclosed
EP-4366767-A2 OLIGONUCLEOTIDES AND VIRAL UNTRANSLATED REGION (UTR) FOR INCREASING EXPRESSION OF TARGET GENES AND PROTEINS Temple University - Of The Commonwealth System of Higher Education (US) 2024-05-15 — — EP disclosed
US-11980672-B2 Heterologous UTR sequences for enhanced mRNA expression MODERNATX, INC. (US) 2024-05-14 — — US disclosed
US-20240139294-A1 METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION UNIV TEMPLE (US) 2024-05-02 — — US disclosed
US-11965162-B2 MicroRNA and inhibitors thereof and methods of treatment THE JOHNS HOPKINS UNIVERSITY (US) 2024-04-23 — — US disclosed
EP-4351623-A1 GENE COMBINATION AS A BROAD SPECTRUM ANTIVIRAL Icahn School of Medicine at Mount Sinai (US) 2024-04-17 — — EP disclosed
US-20240100188-A1 REGULATORY SYSTEM FOR EXPRESSION OF A GENE OF INTEREST IN A TARGET CELL AND METHOD OF USE THEREOF ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-03-28 — — US disclosed
US-20240078661-A1 RNA MOLECULES, METHODS OF PRODUCING CIRCULAR RNA, AND TREATMENT METHODS UNIV CORNELL (US) 2024-03-07 — — US disclosed
WO-2024015729-A1 REGULATORY SYSTEM FOR EXPRESSION OF A GENE OF INTEREST IN A TARGET CELL AND METHOD OF USE THEREOF ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-01-18 — — WO disclosed
US-20160017301-A1 METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-01-21 — — US disclosed
WO-2015031775-A1 METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2015-03-05 — — WO disclosed
EP-1200097-B1 METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION VIGILENT TECHNOLOGIES (FR) 2014-01-08 — — EP disclosed
US-20110143397-A1 RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-06-16 — — US disclosed
EP-1944321-A2 Methods and compositions for determining the purity of chemically synthesized nucleic acids North Carolina State University (US) 2008-07-16 — — EP disclosed
US-6727059-B1 ADMINISTERING A NUCLEOSIDE ANALOG THAT HAS A 3' HYDROXYL GROUP LOCATED ON THE C3' CARBON OF THE 2'-DEOXYRIBOSE, FOR EXAMPLE DUTP; FOR RETROID VIRUS INFECTIONS SUCH AS HIV; MIXTURE WITH REVERSE TRANSCRIPTASE INHIBITORS SUCH AS AZT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2004-04-27 — — US disclosed
EP-1261734-A1 GENOMIC ANALYSIS OF tRNA GENE SETS Montclair Group (US) 2002-12-04 — — EP disclosed
US-20020001804-A1 Genomic analysis of tRNA gene sets TAO BIOSCIENCES, LLC 2002-01-03 — — US disclosed
US-20010049103-A1 Platform for the discovery of the bacterial genes involved in RNA modification TAO BIOSCIENCES, LLC 2001-12-06 — — US disclosed
WO-2001062955-A1 GENOMIC ANALYSIS OF tRNA GENE SETS MONTCLAIR GROUP (US) 2001-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11980672-B2 Heterologous UTR sequences for enhanced mRNA expression RNGTT, UPF1, RNMT TARS1 842/4885ADORA3 3679/4885P2RY12 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.